William D. Baird III Sells 5,092 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVTGet Free Report) CEO William D. Baird III sold 5,092 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $25,205.40. Following the completion of the sale, the chief executive officer now owns 1,121,034 shares in the company, valued at $5,549,118.30. This represents a 0.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

2seventy bio Stock Performance

Shares of NASDAQ TSVT opened at $4.96 on Thursday. The firm has a market cap of $255.88 million, a PE ratio of -2.67 and a beta of 1.73. The firm has a fifty day moving average of $2.85 and a 200 day moving average of $3.69. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99.

Analyst Ratings Changes

TSVT has been the topic of a number of recent analyst reports. Leerink Partners restated a “market perform” rating and issued a $5.00 price target (down from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. Leerink Partnrs cut shares of 2seventy bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 11th. Morgan Stanley lowered their target price on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Friday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 2seventy bio in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.67.

View Our Latest Report on 2seventy bio

Institutional Investors Weigh In On 2seventy bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in TSVT. Erste Asset Management GmbH purchased a new stake in shares of 2seventy bio during the third quarter worth $25,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of 2seventy bio during the fourth quarter worth $32,000. BNP Paribas Financial Markets purchased a new stake in shares of 2seventy bio during the fourth quarter worth $35,000. ProShare Advisors LLC purchased a new stake in shares of 2seventy bio during the fourth quarter worth $48,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of 2seventy bio during the fourth quarter worth $52,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

(Get Free Report)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.

See Also

Insider Buying and Selling by Quarter for 2seventy bio (NASDAQ:TSVT)

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.